Efficacy of the Multi-Target Compound E153 in Relieving Pain and Pruritus of Different Origins.
histamine H3 receptor
itch
pain
pruritus
sigma receptors
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
17 Oct 2023
17 Oct 2023
Historique:
received:
18
08
2023
revised:
04
10
2023
accepted:
13
10
2023
medline:
28
10
2023
pubmed:
28
10
2023
entrez:
28
10
2023
Statut:
epublish
Résumé
Itch and pain are closely related but distinct sensations that share largely overlapping mediators and receptors. We hypothesized that the novel, multi-target compound E153 has the potential to attenuate pain and pruritus of different origins. After the evaluation of sigma receptor affinity and pharmacokinetic studies, we tested the compound using different procedures and models of pain and pruritus. Additionally, we used pharmacological tools, such as PRE-084, RAMH, JNJ 5207852, and S1RA, to precisely determine the role of histamine H
Identifiants
pubmed: 37895952
pii: ph16101481
doi: 10.3390/ph16101481
pmc: PMC10609854
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Curr Pharm Des. 2009;15(15):1711-6
pubmed: 19442185
Front Pharmacol. 2019 Jun 12;10:634
pubmed: 31249525
Int J Dermatol. 2020 Feb;59(2):159-164
pubmed: 31605395
Front Syst Neurosci. 2012 May 04;6:33
pubmed: 22586376
Int J Biochem Cell Biol. 2007;39(3):490-6
pubmed: 17194618
Physiol Behav. 2017 Feb 1;169:22-32
pubmed: 27865771
Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1657-E1666
pubmed: 29378958
Neuroscience. 2011 Sep 8;190:89-102
pubmed: 21689731
Neuropharmacology. 2016 Jul;106:1-2
pubmed: 27089982
Prog Neurobiol. 2021 Jan;196:101894
pubmed: 32777329
Handb Exp Pharmacol. 2007;(177):3-28
pubmed: 17087118
Annu Rev Physiol. 2018 Feb 10;80:189-217
pubmed: 28961064
Neuropharmacology. 2017 Oct;125:181-188
pubmed: 28751195
Toxicol Appl Pharmacol. 2017 Mar 15;319:12-21
pubmed: 28132918
Front Pharmacol. 2019 Jun 12;10:613
pubmed: 31263413
Neurosci Bull. 2018 Feb;34(1):178-185
pubmed: 28389872
Inflamm Res. 2017 Jan;66(1):79-95
pubmed: 27766379
Brain Res Rev. 2009 Apr;60(1):90-113
pubmed: 19150465
Behav Pharmacol. 2014 Jun;25(3):226-35
pubmed: 24776490
Neuroscience. 2010 Mar 10;166(1):292-304
pubmed: 20006972
Neuropharmacology. 2013 Jul;70:131-40
pubmed: 23380305
Br J Pharmacol. 2020 Feb;177(3):469-489
pubmed: 30341770
J Allergy Clin Immunol. 2003 Oct;112(4 Suppl):S53-9
pubmed: 14530789
Epilepsia. 2020 Oct;61(10):2119-2128
pubmed: 32929733
J Pharmacol Exp Ther. 2012 Oct;343(1):13-20
pubmed: 22729221
Annu Rev Neurosci. 2020 Jul 8;43:187-205
pubmed: 32075517
J Pain. 2005 Mar;6(3):193-200
pubmed: 15772913
J Physiol. 2017 Jun 1;595(11):3651-3666
pubmed: 28217875
Pharmacol Rep. 2015 Jun;67(3):593-9
pubmed: 25933974
Pharmacol Res. 2016 Nov;113(Pt A):686-694
pubmed: 27720932
N Engl J Med. 2004 Nov 18;351(21):2203-17
pubmed: 15548781
Br J Pharmacol. 2018 Jul;175(14):2897-2910
pubmed: 29486058
Nat Commun. 2020 Jun 16;11(1):3052
pubmed: 32546780
Pharmacol Biochem Behav. 2015 Jun;133:99-110
pubmed: 25847619
Nat Neurosci. 2013 Feb;16(2):174-82
pubmed: 23263443
Sci Rep. 2016 Nov 25;6:37835
pubmed: 27886264
Eur J Pain. 2018 Jan;22(1):127-141
pubmed: 28877402
Int J Biochem Cell Biol. 2020 Sep;126:105803
pubmed: 32668330
Trends Neurosci. 2020 May;43(5):311-325
pubmed: 32353335
Pharmacol Res. 2021 Jan;163:105339
pubmed: 33276102
Br J Pharmacol. 2004 May;142(2):374-80
pubmed: 15066908
Curr Protoc Neurosci. 2007 Oct;Chapter 8:Unit 8.9
pubmed: 18428666
J Dermatol Sci. 2017 Aug;87(2):130-137
pubmed: 28495120
ACS Chem Neurosci. 2017 Aug 16;8(8):1801-1811
pubmed: 28644012
Eur J Pharmacol. 2017 Feb 15;797:83-93
pubmed: 28095324
Front Pharmacol. 2019 Apr 24;10:422
pubmed: 31068818
Pain Ther. 2017 Dec;6(Suppl 1):25-33
pubmed: 29178034
J Pharmacol Exp Ther. 2011 Jan;336(1):30-7
pubmed: 20864501
Pharmacol Res. 2014 Dec;90:58-66
pubmed: 25304183
Biochem Pharmacol. 2007 Apr 15;73(8):1182-94
pubmed: 17276409
CNS Neurosci Ther. 2016 Feb;22(2):88-101
pubmed: 26663896
J Pharmacol Exp Ther. 2007 Jun;321(3):1032-45
pubmed: 17327487
Nat Rev Neurosci. 2019 Nov;20(11):667-685
pubmed: 31537912
Front Pharmacol. 2019 Feb 22;10:136
pubmed: 30853912
Neurosci Bull. 2017 Aug;33(4):423-435
pubmed: 27783328
Eur J Pharmacol. 2008 Feb 26;581(1-2):86-96
pubmed: 18190906
Lancet. 1999 May 8;353(9164):1610-5
pubmed: 10334274
Pflugers Arch. 2010 Apr;459(5):657-69
pubmed: 20162302
Front Pharmacol. 2017 Oct 12;8:709
pubmed: 29075190
Neuropharmacology. 2019 Jan;144:244-255
pubmed: 30359639
Neuropharmacology. 2009 Jun;56(8):1131-7
pubmed: 19345233
Br J Dermatol. 2003 Jul;149(1):17-22
pubmed: 12890190
Trends Neurosci. 2014 Mar;37(3):159-68
pubmed: 24486025
Neuropharmacology. 2011 May;60(6):886-91
pubmed: 21237180
Proc Natl Acad Sci U S A. 2019 May 21;116(21):10525-10530
pubmed: 31068464
Molecules. 2021 Jun 11;26(12):
pubmed: 34208297
Bioorg Med Chem. 2017 Oct 15;25(20):5341-5354
pubmed: 28797771
J Pain. 2009 May;10(5):534-41
pubmed: 19231296
Br J Pharmacol. 2020 Feb;177(3):580-599
pubmed: 31046146
J Dermatolog Treat. 2022 May;33(3):1554-1557
pubmed: 33084462
Pflugers Arch. 2013 Dec;465(12):1671-85
pubmed: 23636773
Neuron. 2018 May 2;98(3):482-494
pubmed: 29723501
Eur J Pharmacol. 2005 Mar 28;511(2-3):207-17
pubmed: 15792790